MA41185B1 - Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc - Google Patents

Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc

Info

Publication number
MA41185B1
MA41185B1 MA41185A MA41185A MA41185B1 MA 41185 B1 MA41185 B1 MA 41185B1 MA 41185 A MA41185 A MA 41185A MA 41185 A MA41185 A MA 41185A MA 41185 B1 MA41185 B1 MA 41185B1
Authority
MA
Morocco
Prior art keywords
acid compounds
hydroxamic acid
compounds
lpxc inhibitors
isoxazole
Prior art date
Application number
MA41185A
Other languages
English (en)
Inventor
Jiping Fu
Xianming Jin
Subramanian Karur
Guillaume Lapointe
Ann Marie Madera
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA41185B1 publication Critical patent/MA41185B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte, de manière générale, à des composés de formule i et à des compositions contenant de tels composés, ainsi qu'à des procédés d'utilisation de tels composés pour traiter les infections bactériennes. Selon certains aspects, l'invention concerne des méthodes et des compositions pouvant être utilisées pour le traitement d'infections provoquées par des bactéries gram-négatives.
MA41185A 2014-12-16 2015-12-15 Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc MA41185B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16
PCT/IB2015/059631 WO2016097995A1 (fr) 2014-12-16 2015-12-15 Composés d'acides d'isoxazole en tant qu'inhibiteurs de lpxc
EP15816893.0A EP3233843B1 (fr) 2014-12-16 2015-12-15 Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc

Publications (1)

Publication Number Publication Date
MA41185B1 true MA41185B1 (fr) 2019-12-31

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41185A MA41185B1 (fr) 2014-12-16 2015-12-15 Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc

Country Status (42)

Country Link
US (3) US9549916B2 (fr)
EP (1) EP3233843B1 (fr)
JP (1) JP6697466B2 (fr)
KR (1) KR20170094214A (fr)
CN (1) CN107001295B (fr)
AR (1) AR107428A1 (fr)
AU (1) AU2015365455B2 (fr)
BR (1) BR112017011422A2 (fr)
CA (1) CA2969803A1 (fr)
CL (1) CL2017001460A1 (fr)
CO (1) CO2017005870A2 (fr)
CR (1) CR20170260A (fr)
CU (1) CU24443B1 (fr)
CY (1) CY1122305T1 (fr)
DK (1) DK3233843T3 (fr)
EA (1) EA032138B1 (fr)
EC (1) ECSP17045737A (fr)
ES (1) ES2756300T3 (fr)
GT (1) GT201700132A (fr)
HR (1) HRP20192009T1 (fr)
HU (1) HUE047225T2 (fr)
IL (1) IL252373B (fr)
JO (1) JO3818B1 (fr)
LT (1) LT3233843T (fr)
MA (1) MA41185B1 (fr)
ME (1) ME03546B (fr)
MX (1) MX2017007980A (fr)
MY (1) MY195743A (fr)
PE (1) PE20171044A1 (fr)
PH (1) PH12017501019B1 (fr)
PL (1) PL3233843T3 (fr)
PT (1) PT3233843T (fr)
RS (1) RS59507B1 (fr)
SG (1) SG11201704053WA (fr)
SI (1) SI3233843T1 (fr)
SM (1) SMT201900631T1 (fr)
SV (1) SV2017005462A (fr)
TN (1) TN2017000207A1 (fr)
TW (1) TWI693215B (fr)
UA (1) UA121225C2 (fr)
UY (1) UY36448A (fr)
WO (1) WO2016097995A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100040T1 (it) 2013-05-17 2021-03-15 Incyte Corp Derivati di bipirazolo come inibitori di jak
SG11201810656WA (en) * 2016-06-14 2018-12-28 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
CN107434766A (zh) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 烷烃羟胺类化合物的合成装置及连续合成方法
KR102830476B1 (ko) 2018-02-16 2025-07-08 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
IL281614B2 (en) 2018-09-20 2024-12-01 Blacksmith Medicines Inc Antibacterial compounds
KR20210093884A (ko) * 2018-11-21 2021-07-28 다이쇼 세이야꾸 가부시끼가이샤 신규 이미다졸 유도체
CN115836065B (zh) 2020-06-02 2025-07-01 因赛特公司 制备jak1抑制剂的方法
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN112603936B (zh) * 2020-12-28 2022-08-02 仲恺农业工程学院 一种抑制气单胞菌属的组合物及其制备方法与应用
US20240166609A1 (en) * 2021-02-11 2024-05-23 Blacksmith Medicines, Inc. Antibacterial compounds
WO2022173756A1 (fr) * 2021-02-11 2022-08-18 Forge Therapeutics, Inc. Composés antibactériens
SI4333840T1 (sl) 2021-05-03 2026-01-30 Incyte Corporation Zaviralci poti jak1 za zdravljenje pruriga nodularisa
JP2024536864A (ja) * 2021-09-28 2024-10-08 ブラックスミス メディシンズ，インク． Ｌｐｘｃ阻害剤およびその使用
WO2024067813A1 (fr) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 Dérivé d'acétylène aromatique, son procédé de préparation et son utilisation pharmaceutique
CN119816496A (zh) * 2022-09-28 2025-04-11 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
DE59009528D1 (de) 1989-09-22 1995-09-21 Basf Ag Carbonsäureamide.
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (fr) 1996-08-16 1998-02-19 Schering Corporation Antigenes de surface de cellules mammaliennes et reactifs qui y sont lies
WO1999020758A1 (fr) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
CA2319236A1 (fr) 1998-02-09 1999-08-12 Genentech, Inc. Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
CA2378179A1 (fr) 1999-07-12 2001-01-18 Genentech, Inc. Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation avec des homologues de ligands et de recepteurs du facteur de necrose tumorale
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
SG2012000667A (en) * 2003-01-08 2015-03-30 Univ Washington Antibacterial agents
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
RU2369636C2 (ru) 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (fr) 2004-06-04 2007-03-28 Duke University Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
CA2693677C (fr) 2007-07-12 2018-02-13 Tolerx, Inc. Therapies combinees utilisant des molecules de liaison au gitr
EP2242773B1 (fr) 2008-02-11 2017-06-14 Cure Tech Ltd. Anticorps monoclonaux pour le traitement de tumeurs
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
WO2010003118A1 (fr) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Protéines de liaison multi-cibles antagonistes du tgf-b
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2328920A2 (fr) 2008-08-25 2011-06-08 Amplimmune, Inc. Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer
WO2010030002A1 (fr) 2008-09-12 2010-03-18 国立大学法人三重大学 Cellule capable d'exprimer un ligand gitr exogène
WO2010032147A2 (fr) 2008-09-19 2010-03-25 Pfizer Inc. Dérivés d'acide hydroxamique utiles comme agents antibactériens
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
CA2774250C (fr) * 2009-10-13 2013-12-17 Pfizer Inc. Derives d'acide hydroxamique a liaison c utiles comme agents antibacteriens
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
US8664401B2 (en) * 2009-12-16 2014-03-04 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EA201390626A1 (ru) 2010-11-10 2013-12-30 Эйкеоджен, Инк. Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
EA024782B1 (ru) 2011-03-07 2016-10-31 Пфайзер Инк. Производные фторпиридинона, полезные в качестве антибактериальных агентов
CA2830866A1 (fr) * 2011-04-08 2012-10-11 Pfizer Inc. Derives d'imidazole, de pyrazole et de triazole, utiles en tant qu'agents antibacteriens
MX2013011526A (es) * 2011-04-08 2013-12-06 Pfizer Derivados de isoxazol utiles como agentes antibacteriales .
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014160649A1 (fr) 2013-03-29 2014-10-02 Novartis Ag Dérivés d'acide hydroxamique utilisés comme inhibiteurs de lpxc pour le traitement d'infections bactériennes

Also Published As

Publication number Publication date
CN107001295B (zh) 2021-02-02
DK3233843T3 (da) 2019-11-18
EA201791353A1 (ru) 2017-10-31
US20180030004A1 (en) 2018-02-01
ES2756300T3 (es) 2020-04-27
AR107428A1 (es) 2018-05-02
CR20170260A (es) 2017-08-21
PH12017501019B1 (en) 2020-06-05
EP3233843A1 (fr) 2017-10-25
SG11201704053WA (en) 2017-06-29
JO3818B1 (ar) 2021-01-31
US9549916B2 (en) 2017-01-24
CU20170084A7 (es) 2017-11-07
US20170088525A1 (en) 2017-03-30
SI3233843T1 (sl) 2019-12-31
IL252373A0 (en) 2017-07-31
ME03546B (fr) 2020-07-20
PH12017501019A1 (en) 2017-12-04
TWI693215B (zh) 2020-05-11
EA032138B1 (ru) 2019-04-30
RS59507B1 (sr) 2019-12-31
US20160166548A1 (en) 2016-06-16
US9815804B2 (en) 2017-11-14
CY1122305T1 (el) 2021-01-27
IL252373B (en) 2019-11-28
MY195743A (en) 2023-02-08
PL3233843T3 (pl) 2020-04-30
LT3233843T (lt) 2019-12-10
CN107001295A (zh) 2017-08-01
JP6697466B2 (ja) 2020-05-20
EP3233843B1 (fr) 2019-10-16
ECSP17045737A (es) 2019-02-28
UA121225C2 (uk) 2020-04-27
US10029994B2 (en) 2018-07-24
SMT201900631T1 (it) 2020-01-14
CA2969803A1 (fr) 2016-06-23
TW201629024A (zh) 2016-08-16
KR20170094214A (ko) 2017-08-17
CU24443B1 (es) 2019-10-04
HUE047225T2 (hu) 2020-04-28
JP2018500333A (ja) 2018-01-11
UY36448A (es) 2016-07-29
AU2015365455B2 (en) 2019-01-17
GT201700132A (es) 2019-10-10
PT3233843T (pt) 2019-11-26
TN2017000207A1 (en) 2018-10-19
SV2017005462A (es) 2018-04-04
CL2017001460A1 (es) 2017-12-22
CO2017005870A2 (es) 2017-10-20
AU2015365455A1 (en) 2017-06-08
WO2016097995A1 (fr) 2016-06-23
MX2017007980A (es) 2017-09-29
HRP20192009T1 (hr) 2020-02-07
BR112017011422A2 (pt) 2018-04-03
PE20171044A1 (es) 2017-07-19

Similar Documents

Publication Publication Date Title
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA39777B1 (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA41013A (fr) Compositions comprenant des souches bactériennes
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MA34963B1 (fr) Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39792B1 (fr) Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
MA38483A1 (fr) Inhibiteurs de l'ido
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
EA202090750A1 (ru) Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами
MX2017012759A (es) Moléculas pequeñas que contienen boro como agentes antiprotozoarios.
MD4599B1 (ro) Săruri de hidroclorură a unui compus antibiotic
MA43263B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs